2008
DOI: 10.1038/nature07475
|View full text |Cite
|
Sign up to set email alerts
|

Frequent in-frame somatic deletions activate gp130 in inflammatory hepatocellular tumours

Abstract: Inflammatory hepatocellular adenomas (IHCA) are benign liver tumours defined by the presence of inflammatory infiltrates and by the elevated expression of inflammatory proteins in tumour hepatocytes1,2. Here we show a striking activation of the IL6 signalling pathway in this tumour type, and sequencing candidate genes pinpointed this response to somatic gain-of-function mutations in the IL6ST gene that encodes the signalling co-receptor gp130. Indeed, 60% of IHCA harbour small in-frame deletions that target th… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1

Citation Types

7
399
2
4

Year Published

2009
2009
2020
2020

Publication Types

Select...
5
4

Relationship

2
7

Authors

Journals

citations
Cited by 430 publications
(418 citation statements)
references
References 36 publications
7
399
2
4
Order By: Relevance
“…15,17 A combination of gp130 alterations and b-catenin mutation is likely in these cases leading to the activation of both pathways. 20 The diffuse glutamine synthetase pattern in these cases is different from focal nodular hyperplasia map-like pattern, which often shows sparing of hepatocytes around the fibrous septa.…”
Section: Discussionmentioning
confidence: 81%
See 1 more Smart Citation
“…15,17 A combination of gp130 alterations and b-catenin mutation is likely in these cases leading to the activation of both pathways. 20 The diffuse glutamine synthetase pattern in these cases is different from focal nodular hyperplasia map-like pattern, which often shows sparing of hepatocytes around the fibrous septa.…”
Section: Discussionmentioning
confidence: 81%
“…15,17,18 Inflammatory hepatocellular adenomas are frequently characterized by in-frame deletions of the interleukin-6 signaling transducer gp130 protein or mutations of activator of transcription 3 (STAT3). 19,20 This leads to constitutive activation of the interleukin-6 pathway and expression of acute phase reactants, serum amyloid-associated protein and C-reactive protein.…”
mentioning
confidence: 99%
“…Immunohistochemistry showed CCL20 expression in macrophages but not in endothelial cells (30). In monocytes/macrophages, CCL20 is a hypoxia-inducible gene as illustrated by ischemic/hypoxic transcriptome studies (31,32), in which it constitutes an important mechanism to promote recruitment of specific leukocyte subsets at pathologic sites. Thus, in SOS, hypoxia possibly triggers CCL20 expression.…”
Section: Discussionmentioning
confidence: 99%
“…2,5 The third group of hepatocellular adenoma, namely inflammatory adenoma (about 50% of all hepatocellular adenomas), harbor somatic gain-offunction mutations in either IL6ST, FRK, JAK1, STAT3, or GNAS genes activating the interleukin-6/ JAK/STAT pathway. 3,6,8,9 They are histologically characterized by sinusoidal dilation, inflammatory infiltrates, and dystrophic vessels often surrounded by fibrotic tissue. An immunohistochemical panel has been developed to allow pathological identification of all three hepatocellular adenoma subgroups and inflammatory adenomas are characterized by an overexpression of the C-reactive and serum amyloid A proteins in tumor hepatocytes.…”
mentioning
confidence: 99%